AU2018364685B2 - Extended release formulations for intra-articular applications - Google Patents

Extended release formulations for intra-articular applications Download PDF

Info

Publication number
AU2018364685B2
AU2018364685B2 AU2018364685A AU2018364685A AU2018364685B2 AU 2018364685 B2 AU2018364685 B2 AU 2018364685B2 AU 2018364685 A AU2018364685 A AU 2018364685A AU 2018364685 A AU2018364685 A AU 2018364685A AU 2018364685 B2 AU2018364685 B2 AU 2018364685B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
optionally
water
oxabicyclo
dichlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018364685A
Other languages
English (en)
Other versions
AU2018364685A1 (en
Inventor
Carlo Castagnoli
Andreas Fisch
Mathilde LORSCHEIDER
Manjali Laxman NEHARKAR
Bernd Ulrich Riebesehl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2018364685A1 publication Critical patent/AU2018364685A1/en
Application granted granted Critical
Publication of AU2018364685B2 publication Critical patent/AU2018364685B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018364685A 2017-11-10 2018-11-08 Extended release formulations for intra-articular applications Active AU2018364685B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762584589P 2017-11-10 2017-11-10
US62/584,589 2017-11-10
US201862743864P 2018-10-10 2018-10-10
US62/743,864 2018-10-10
PCT/IB2018/058788 WO2019092637A1 (en) 2017-11-10 2018-11-08 Extended release formulations for intra-articular applications

Publications (2)

Publication Number Publication Date
AU2018364685A1 AU2018364685A1 (en) 2020-03-26
AU2018364685B2 true AU2018364685B2 (en) 2021-05-20

Family

ID=64402238

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018364685A Active AU2018364685B2 (en) 2017-11-10 2018-11-08 Extended release formulations for intra-articular applications

Country Status (23)

Country Link
US (1) US20210177824A1 (enExample)
EP (1) EP3706710B1 (enExample)
JP (1) JP7284750B2 (enExample)
KR (1) KR20200087138A (enExample)
CN (1) CN111278410A (enExample)
AU (1) AU2018364685B2 (enExample)
CA (1) CA3075722A1 (enExample)
CL (1) CL2020001156A1 (enExample)
DK (1) DK3706710T3 (enExample)
ES (1) ES2981903T3 (enExample)
FI (1) FI3706710T3 (enExample)
HR (1) HRP20240808T1 (enExample)
HU (1) HUE066971T2 (enExample)
IL (2) IL274149B2 (enExample)
LT (1) LT3706710T (enExample)
MX (2) MX2020004477A (enExample)
PL (1) PL3706710T3 (enExample)
PT (1) PT3706710T (enExample)
RS (1) RS65659B1 (enExample)
SA (1) SA520411881B1 (enExample)
SI (1) SI3706710T1 (enExample)
TW (2) TWI813597B (enExample)
WO (1) WO2019092637A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3891154B1 (en) * 2018-12-06 2023-08-16 Novartis AG 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
KR20220076371A (ko) * 2020-11-30 2022-06-08 주식회사 엘지화학 캐스파제 저해제를 함유하는 주사용 조성물 및 이의 제조 방법
KR20240133027A (ko) 2023-02-28 2024-09-04 주식회사 포스테라헬스사이언스 올리고펩타이드를 포함하는 서방형 입자 및 이의 제조 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012172072A1 (en) * 2011-06-17 2012-12-20 Ares Trading S.A. Freeze-dried formulations of fgf-18
US20170239227A1 (en) * 2014-05-13 2017-08-24 Novartis Ag Compounds and compositions for inducing chondrogenesis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012172072A1 (en) * 2011-06-17 2012-12-20 Ares Trading S.A. Freeze-dried formulations of fgf-18
US20170239227A1 (en) * 2014-05-13 2017-08-24 Novartis Ag Compounds and compositions for inducing chondrogenesis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
D Ramya Devi ET AL, Journal of Pharmaceutical Sciences and Research, Cuddalore, (2013-08-01), page 159, URL: https://pdfs.semanticscholar.org/3252/bcbb2763f63d3ff603ffd9dfecf6d2bcf0a1.pdf, (2019-01-23) *

Also Published As

Publication number Publication date
SI3706710T1 (sl) 2024-08-30
US20210177824A1 (en) 2021-06-17
LT3706710T (lt) 2024-07-10
JP2021502337A (ja) 2021-01-28
IL305541A (en) 2023-10-01
FI3706710T3 (fi) 2024-07-08
RU2020115439A3 (enExample) 2021-12-10
MX2020004477A (es) 2020-08-03
EP3706710B1 (en) 2024-04-10
RS65659B1 (sr) 2024-07-31
HUE066971T2 (hu) 2024-09-28
EP3706710A1 (en) 2020-09-16
CN111278410A (zh) 2020-06-12
TW201922245A (zh) 2019-06-16
RU2020115439A (ru) 2021-12-10
TW202400164A (zh) 2024-01-01
AU2018364685A1 (en) 2020-03-26
CL2020001156A1 (es) 2020-10-30
PL3706710T3 (pl) 2024-08-05
MX2023007036A (es) 2023-06-28
IL274149B1 (en) 2023-10-01
TWI813597B (zh) 2023-09-01
JP7284750B2 (ja) 2023-05-31
PT3706710T (pt) 2024-06-27
WO2019092637A1 (en) 2019-05-16
IL274149A (en) 2020-06-30
KR20200087138A (ko) 2020-07-20
SA520411881B1 (ar) 2024-01-04
IL274149B2 (en) 2024-02-01
BR112020008806A2 (pt) 2020-10-20
CA3075722A1 (en) 2019-05-16
HRP20240808T1 (hr) 2024-09-27
ES2981903T3 (es) 2024-10-14
DK3706710T3 (da) 2024-07-08

Similar Documents

Publication Publication Date Title
CN102215874B (zh) 活性剂的聚合物递送系统
US20070077286A1 (en) Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle
SG176055A1 (en) Compositions and methods for drug delivery
US20150024031A1 (en) Methods And Compositions For Reducing Pain, Inflammation, And/Or Immunological Reactions Associated With Parenterally Administering A Primary Therapeutic Agent
KR20100057007A (ko) 치료제의 마이셀 캡슐화
AU2018364685B2 (en) Extended release formulations for intra-articular applications
US8883177B2 (en) Pharmaceutical compositions for parenteral administration
US12186427B2 (en) Fulvestrant formulations and methods of their use
IL292079B2 (en) Aripiprazole prodrug compositions and uses thereof
JP2007515425A (ja) 医薬組成物
RU2786830C2 (ru) Препараты с пролонгированным высвобождением для внутрисуставного введения
HK40027680A (en) Extended release formulations for intra-articular applications
HK40027680B (en) Extended release formulations for intra-articular applications
US11590077B2 (en) Fulvestrant formulations and methods of their use
WO2023046731A1 (en) Antipsychotic injectable extended-release composition
BR112020008806B1 (pt) Composição farmacêutica adequada para injeção intra-articular, seu uso, e kit
RU2800869C2 (ru) Составы фулвестранта и способы их применения
WO2024224373A1 (en) Levothyroxine dispersions
CN120513090A (zh) 卡利拉嗪的长效性注射用(lai)组合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)